**Correspondence:** Dr Zu, Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, Harbin 150040, People's Republic of China (yujie\_fu2002@yahoo.com).

Author Contributions: Study concept and design: Fu, Chen, Zu, and Efferth. Acquisition of data: Chen and Z. Liu. Analysis and interpretation of data: X. Liu, Y. Liu, and Yao. Drafting of the manuscript: Fu, Chen, Z. Liu, X. Liu, Y. Liu, and Efferth. Critical revision of the manuscript for important intellectual content: Zu, Yao, and Efferth. Statistical analysis: Fu and Chen. Obtained funding: Fu and Zu. Administrative, technical, and material support: Fu. Study supervision: Fu, Chen, Zu, Z. Liu, X. Liu, Y. Liu, Yao, and Efferth.

Financial Disclosure: None reported.

**Funding/Support:** This study was funded by grants 30770231 from the National Natural Science Foundation of China, Beijing, China; JC200704 from the Heilongjiang Province Science Foundation for Excellent Youths, Harbin, China; 108049 from the Key Project of Chinese Ministry of Education, Beijing; 2006BAD18B0401 from the National Key Technology Research and Development Program, Beijing; 2006-4-75 from the Innovative Program for Importation of International Advanced Agricultural Science and Technology, National Forestry Bureau, Beijing; and 2006RFXXS001 from the Research Foundation for Science and Technology Innovation Talents of Harbin.

**Role of the Sponsors:** The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.

- 1. Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol. 1995;32(5, pt 3):S15-S25.
- Ahmad N, Alam MK, Shehbaz A, et al. Antimicrobial activity of clove oil and its potential in the treatment of vaginal candidiasis. J Drug Target. 2005;13 (10):555-561.
- Falcocchio S, Ruiz C, Pastor FI, Saso L, Diaz P. Propionibacterium acnes GehA lipase, an enzyme involved in acne development, can be successfully inhibited by defined natural substances. J Mol Catal B Enzym. 2006;40(3-4):132-137.
- Higaki S. Lipase inhibitors for the treatment of acne. J Mol Catal B Enzym. 2003;22(5-6):377-384.
- Brüggemann H, Henne A, Hoster F, et al. The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science. 2004;305(5684): 671-673.

## Long-term Maintenance of a Successful Occupational Sun Safety Intervention

**S** kin cancer prevention specialists should attempt to reduce UV radiation (UVR) exposure among outdoor workers, as pointed out in a recent review.<sup>1</sup> To address this need, Project SUNWISE,<sup>2,3</sup> a randomized controlled sun safety intervention trial with Southern Californian US Postal Service letter carriers, was conducted from 2001 through 2004.

**Methods.** The intervention consisted of providing free sunscreen, free wide-brim hats, a series of 6 brief on-site educational sessions, and sun safety prompts. The primary outcome measures were validated questionnaire items that asked participants how often they had used specific sun protection strategies over the past 5 workdays while delivering mail.<sup>23</sup> The questionnaires were administered at baseline and 3, 12, 24, and 36 months after baseline. The 5 response options ranged from "never" to "always"; we considered "always" as "consistent use" in analyses.

**Results.** At the 2-year follow-up evaluation, participants at the intervention postal stations had significantly higher rates of consistent sunscreen and widebrim hat use than those at control stations.<sup>2</sup> Details about the study procedures and sample characteristics have been published previously.<sup>2</sup> Immediately following the 2-year evaluation, control station participants received the free items and 3 of the educational sessions (ie, introduction and protection strategies, sun safety for eyes, and review and encouragement to maintain sun safety practices). At the intervention stations, we continued to provide free sunscreen during that year. Herein, we describe the behavioral outcomes at the 3-year follow-up evaluation.

Evaluation cohort retention rates (of those completing questionnaires) from the 2- to 3- year follow-up periods were 93.2% (927 of 994) for the intervention group and 94.4% (1130 of 1196) for the control group. The trends over 3 years in 2 key outcomes-consistent use of sunscreen and wide-brim hats-were analyzed using generalized linear mixed models treating 3 months, 1 year, 2 years, and 3 years as a set of repeated measures on each postal worker. In addition, we adjusted for postal workers clustered within post offices within a multilevel model. The intraclass correlation coefficients for sunscreen and hats were 0.015 and 0.067, respectively. All analyses were adjusted for the baseline level of the corresponding outcome variable. For each analysis, we tested (1) the time  $\times$  condition interaction to determine if the intervention effect remained constant over time and (2) the condition main effect. Consistent sunscreen use rates for intervention participants at the 2- and 3- year follow-up periods were 39.2% and 38.3%, respectively, and for control participants, the rates were 26.3% and 34.3%, respectively. Wide-brim hat use rates for intervention participants during these periods were 40.0% and 43.8%, respectively, and for control participants, the rates were 22.3% and 33.0%, respectively. Results of the analyses for each of these outcomes showed significant time  $\times$  condition interaction effects (P<.001 for all), in-

Table. Results of Generalized, Linear,
Mixed-Model Analyses During 3-Year Follow-up <sup>a</sup>

Follow-up Period	Sunscreen	Wide-Brim Hat
3 mo	2.69 (2.13-3.39)	3.13 (2.43-4.03)
1 y	2.06 (1.64-2.58)	2.40 (1.87-3.09)
2 у	1.96 (1.54-2.48)	2.64 (2.03-3.43)
3 у	1.08 (0.85-1.36)	1.44 (1.12-1.85)

<sup>a</sup> All data are reported as odds ratios (95% confidence intervals) for the intervention group always using the listed sun protection vs the control group; all models were adjusted for baseline level of the outcome variable and postal station clustering.

88

Downloaded from www.archdermatol.com , on July 16, 2009 ©2009 American Medical Association. All rights reserved.

<sup>(</sup>REPRINTED) ARCH DERMATOL/VOL 145 (NO. 1), JAN 2009 WWW.ARCHDERMATOL.COM

dicating that the differences between the conditions were changing over time. The **Table** lists these findings. For both behaviors, the change in the odds ratios from year 2 to year 3 was not due to a lowered use rate among intervention participants but rather to an increased rate among control group participants.

**Comment.** We are encouraged that intervention effects were maintained at least 1 year after the program ended and that once the control participants received the intervention, their consistent use of sun protection increased substantially.

Joni A. Mayer, PhD Donald J. Slymen, PhD Elizabeth J. Clapp, MPH Latrice C. Pichon, MPH John P. Elder, PhD, MPH James F. Sallis, PhD Lawrence F. Eichenfield, MD Martin A. Weinstock, MD, PhD

**Correspondence:** Dr Mayer, 9245 Sky Park Court, Ste 220, San Diego, CA 92123 (jmayer@mail.sdsu.edu). **Author Contributions:** *Study concept and design:* Mayer, Slymen, Clapp, Elder, Sallis, Eichenfield, and Weinstock. *Acquisition of data:* Mayer and Pichon. *Analysis and interpretation of data:* Mayer and Slymen. *Drafting of the manuscript:* Mayer, Slymen, Clapp, Pichon, Elder, Sallis, Eichenfield, and Weinstock. *Critical revision of the manuscript for important intellectual content:* Mayer. *Statistical analysis:* Slymen. *Obtained funding:* Mayer, Elder, and Sallis. *Administrative, technical, and material support:* Clapp. *Study supervision:* Clapp and Pichon. **Financial Disclosure:** None reported.

**Funding/Support:** This study was supported by grants R01CA085980, R01CA085980S1, R01CA085980S2, and K05100051 from the National Institutes of Health, National Cancer Institute, Bethesda, Maryland.

**Role of the Sponsors:** The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.

Additional Contributions: Dr Eichenfield served as a dermatologist expert consultant, and Dr Weinstock provided dermatoepidermal expertise. Laura Eckhardt, MPH, Sam Oh, MPH, Gabriel Galindo, MPH, Cynthia Balderrama, BA, and April Achter provided scientific contributions to this study. Our contacts at the US Postal Service (USPS) in Southern California and the National Association of Letter Carriers provided valuable contributions, and the USPS letter carriers participated in the evaluation. Debra Rubio, BA, provided assistance in manuscript preparation.

- Glanz K, Buller DB, Saraiya M. Reducing ultraviolet radiation exposure among outdoor workers: state of the evidence and recommendations. *Environ Health*. 2007;6:22.
- Mayer JA, Slymen DJ, Clapp EJ, et al. Promoting the sun safety of United States Postal Service letter carriers: impact of a two-year intervention. *Am J Public Health.* 2007;97(3):559-565.
- Oh SS, Mayer JA, Lewis EC, et al. Validating outdoor workers' self-report of sun protection. *Prev Med.* 2004;39(4):798-803.

## **COMMENTS AND OPINIONS**

## Lymphangiogenesis Induced by Surgery: A Risk for Melanoma Metastasis

**I** read with interest the editorial of Sondak and Messina<sup>1</sup> on lymphangiogenesis and melanoma metastasis. Lymphangiogenesis has possibly become the crucial problem of melanoma management. Since vascular endothelial growth factors (VEGFs) A, C, and D induce lymphangiogenesis in experimental wounds in adult animals,<sup>2,3</sup> it is possible that wounding stimulates lymphangiogenesis. The slow healing of chronic diabetic ulcers is related to the downregulation of VEGFs, and the administration of VEGF accelerates wound healing.<sup>4</sup> Based on these observations, I wish to offer the hypothesis that surgery may promote the same lymphangiogenic activity that promotes the dissemination of malignant cells.

Of course, surgery cannot be abandoned because precise diagnosis cannot be made without excising the tumor. However, new procedures should be used to limit the need for extensive surgery. For example, immunofluorescence analysis even of routine paraffin sections of the lymphatic endothelial hyaluronan receptor 1 (a specific marker of tumor-associated lymphatics) will provide a relatively simple means to determine which patient is destined to experience metastasis.<sup>5</sup> More importantly, immunofluorescence and other techniques may be used to recruit patients who might be eligible for antilymphangiogenic therapy. Soluble VEGFR-E-IgG fusion proteins and neutralizing anti-VEGF-D antibodies provide novel therapeutic opportunities for preventing dissemination of metastatic cells. A successful case of the use of bevacizumab has been reported,<sup>6</sup> but a trial of presurgical treatment with antilymphangiogenic drugs offers hope of limiting metastasis for our patients with melanoma.

## Alfredo Rebora, MD

**Correspondence:** Dr Rebora, 7, Viale Benedetto XV, 16132 Genova, Italy (rebdermo@unige.it). **Financial Disclosure:** None reported.

- Sondak VK, Messina JL. Lymphangiogenesis: host and tumor factors in nodal metastasis. Arch Dermatol. 2008;144(4):536-537.
- Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. *Am J Pathol.* 2000;156(5):1499-1504.
- 3. Hong YK, Lange-Asschenfeldt B, Velasco P, et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004;18(10):1111-1113.
- Zheng Y, Watanabe M, Kuraishi T, Hattori S, Kai C, Shibuya M. Chimeric VEGF-ENZ7/PIGF specifically binding to VEGFR-2 accelerates skin wound healing via enhancement of neovascularization. *Arterioscler Thromb Vasc Biol.* 2007;27(3):503-511.
- Pepper MS, Tille JC, Nisato R, Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 2003;314(1):167-177.
- Jaissle GB, Ulmer A, Henke-Fahle S, Fierlbeck G, Bartz-Schmidt KU, Szurman P. Suppression of melanoma-associated neoangiogenesis by bevacizumab. *Arch Dermatol.* 2008;144(4):525-527.

89